GlassScriptPhysician profile
Sheena Chatha
NPI 1588997787
$3,195.03
in general payments reported to CMS, 2019-2025
28 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $397 · 2021: $351 · 2022: $301 · 2023: $569 · 2024: $933 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.97 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $522.59 | 2020-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $276.58 | 2023-2025 | Minimed 780g |
| Lilly USA, LLC | $240.76 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $227.30 | 2019-2025 | Tepezza, Evenity |
| Dexcom, INC. | $195.23 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $175.90 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.99 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.13 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $132.17 | 2021 | |
| Mannkind Corporation | $59.40 | 2019 | |
| Neurocrine Biosciences, INC. | $50.82 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $48.18 | 2022-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $45.70 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $43.66 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $40.94 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Intuity Medical INC | $37.97 | 2022 | |
| Amneal Pharmaceuticals LLC | $32.43 | 2021-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $30.42 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $27.78 | 2025 | Yorvipath |
| Insulet Corporation | $26.95 | 2021-2024 | Omnipod |
| Abbvie INC. | $24.49 | 2023 | |
| Ascensia Diabetes Care US INC. | $23.17 | 2025 | |
| Sequel Med Tech, LLC | $19.63 | 2025 | Twiist |
| Kyowa Kirin, INC. | $19.39 | 2024 | Crysvita |
| Pfizer INC. | $18.73 | 2023 | |
| Tolmar, INC. | $15.03 | 2024 | |
| Esperion Therapeutics, INC. | $14.72 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Chatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.